Circulating tumor DNA (ctDNA) analyses in patients with HER2-positive biliary tract cancer (BTC) treated with trastuzumab deruxtecan (T-DXd): Exploratory results from the HERB trial

被引：0

作者：

Ohba, Akihiro

Morizane, Chigusa

Kawamoto, Yasuyuki

Komatsu, Yoshito

Ueno, Makoto

Kobayashi, Satoshi

Ikeda, Masafumi

Sasaki, Mitsuhito

Furuse, Junji

Okano, Naohiro

Hiraoka, Nobuyoshi

Yoshida, Hiroshi

Kuchiba, Aya

Sadachi, Ryo

Nakamura, Kenichi

Matsui, Naoko

Nakamura, Yoshiaki

Okamoto, Wataru

Yoshino, Takayuki

Okusaka, Takuji

机构：

[1] Natl Canc Ctr, Tokyo, Japan

[2] Hokkaido Univ Hosp, Sapporo, Japan

[3] Kanagawa Canc Ctr, Yokohama, Japan

[4] Natl Canc Ctr Hosp East, Kashiwa, Japan

[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[6] Kyorin Univ, Fac Med, Tokyo, Japan

[7] Hiroshima Univ Hosp, Hiroshima, Japan

[8] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

4097

引用

页数：1

共 50 条

[21] Durable clinical and radiographic responses in a series of patients with HER2+Breast Cancer (BC) Leptomeningeal Disease (LMD) treated with trastuzumab deruxtecan (T-DXd). [J].

Alder, Laura ;

Trapani, Dario ;

Van Swearingen, Amanda ;

Khasraw, Mustafa ;

Anders, Carey ;

Lin, Nancy ;

Sammons, Sarah .

CANCER RESEARCH, 2022, 82 (12)

[22] Association of early tumor shrinkage with survival in patients with HER2-positive advanced gastric cancer treated with trastuzumab deruxtecan. [J].

Fukuda, Koshiro ;

Ooki, Akira ;

Osumi, Hiroki ;

Fukuoka, Shota ;

Yoshino, Koichiro ;

Tamba, Mikako ;

Udagawa, Shohei ;

Shimozaki, Keitaro ;

Ogura, Mariko ;

Wakatsuki, Takeru ;

Chin, Keisho ;

Fujishiro, Mitsuhiro ;

Shinozaki, Eiji ;

Yamaguchi, Kensei .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) :360-360

[23] A phase II trial of [fam-] trastuzumab deruxtecan (T-DXd, DS-8201a) in subjects with HER2-positive, unresectable, or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma [J].

Fuchs, Charles S. ;

Shahidi, Javad ;

Mathew, Lijoy ;

Qin, Amy ;

Van Cutsem, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)

[24] An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01,-02, and-03 [J].

Krop, Ian E. ;

Wildiers, Hans ;

Hurvitz, Sara A. ;

Cortes, Javier ;

Im, Seock-Ah ;

Iwata, Hiroji ;

Andre, Fabrice ;

Saura, Cristina ;

Modi, Shanu ;

Kim, Sung-Bae ;

Egorov, Anton ;

Mathias, Elton ;

Cathcart, Jillian ;

Cagnazzo, Antonio ;

Cheng, Yingkai ;

Park, Yeon Hee .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[25] Safety and pharmacokinetic results from a phase 1, multicenter, open-label study of [fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with advanced HER2-positive breast cancer [J].

Chang, Dwan-Ying ;

Lin, Chia-Chi ;

Chen, Tom Wei-Wu ;

Lin, Ching-Hung ;

Lee, Jih-Hsiang ;

Chao, Ta-Chung ;

Liu, Chun-Yu ;

Achiwa, Issei ;

Kamiyama, Emi ;

Okuda, Yasuyuki ;

Lee, Caleb ;

Chao, Yee .

MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)

[26] Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial [J].

Perez-Garcia, Jose Manuel ;

Vaz Batista, Marta ;

Cortez, Patricia ;

Ruiz-Borrego, Manuel ;

Cejalvo, Juan Miguel ;

de la Haba-rodriguez, Juan ;

Garrigos, Laia ;

Racca, Fabricio ;

Servitja, Sonia ;

Blanch, Salvador ;

Gion, Maria ;

Nave, Monica ;

Fernandez-Abad, Maria ;

Martinez-Bueno, Alejandro ;

Llombart-Cussac, Antonio ;

Sampayo-Cordero, Miguel ;

Malfettone, Andrea ;

Cortes, Javier ;

Braga, Sofia .

NEURO-ONCOLOGY, 2023, 25 (01) :157-166

[27] NEURON-SPECIFIC ENOLASE (NSE) AND S100 SERUM LEVELS IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER2-POSITIVE BREAST CANCER TREATED WITH TRASTUZUMAB-DERUXTECAN (T-DXD): A BIOMARKER ANALYSIS FROM THE TUXEDO-1 TRIAL [J].

Berghoff, A. S. ;

Bartsch, R. ;

Furtner, J. ;

Marhold, M. ;

Bergen, E. S. ;

Roider-Schur, S. ;

Starzer, A. M. ;

Forstner, H. ;

Rottenmanner, B. ;

Dieckmann, K. ;

Bago-Horvath, Z. ;

Widhalm, G. ;

Ilhan-Mutlu, A. ;

Minichsdorfer, C. ;

Fuereder, T. ;

Singer, C. F. ;

Weltermann, A. ;

Haslacher, H. ;

Szekeres, T. ;

Puhr, R. ;

Preusser, M. .

NEURO-ONCOLOGY, 2022, 24

[28] A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11) [J].

Harbeck, Nadia ;

Boileau, Jean-Francois ;

Modi, Shanu ;

Kelly, Catherine M. ;

Ohno, Shinji ;

Wu, Jiong ;

Brekenridge, Mark ;

Herbolsheimer, Pia ;

Yu, Tinghui ;

Pusztai, Lajos .

CANCER RESEARCH, 2022, 82 (04)

[29] Phase II study of trastuzumab deruxtecan in patients with HER2-positive recurrent/metastatic salivary gland cancer: Results from the MYTHOS trial [J].

Kinoshita, I. ;

Kano, S. ;

Honma, Y. ;

Kiyota, N. ;

Tahara, M. ;

Takahashi, S. ;

Ito, Y. ;

Hatanaka, Y. ;

Matsuno, Y. ;

Dosaka-Akita, H. .

ANNALS OF ONCOLOGY, 2024, 35 :S613-S614

[30] Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study) [J].

Gavin P. Dowling ;

Sinead Toomey ;

Philip Bredin ;

Imelda Parker ;

Eibhlin Mulroe ;

Jacinta Marron ;

Olivia McLoughlin ;

Ausra Teiserskiene ;

Colm Power ;

Anne Marie O’Shea ;

Megan Greally ;

Patrick G. Morris ;

Deirdre Duke ;

Arnold D. K. Hill ;

Bryan T. Hennessy .

BMC Cancer, 24

← 1 2 3 4 5 →